Novocure Ltd

NASDAQ NVCR

Data sourced from

and

Download Data

Novocure Ltd Gross Profit for the quarter ending March 31, 2024: USD 104.81 M

Novocure Ltd Gross Profit is USD 104.81 M for the quarter ending March 31, 2024, a 13.23% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Novocure Ltd Gross Profit for the quarter ending March 31, 2023 was USD 92.57 M, a -15.71% change year over year.
Novocure Ltd Gross Profit for the quarter ending March 31, 2022 was USD 109.82 M, a 1.39% change year over year.
Novocure Ltd Gross Profit for the quarter ending March 31, 2021 was USD 108.31 M, a 40.06% change year over year.
Novocure Ltd Gross Profit for the quarter ending March 31, 2020 was USD 77.33 M, a 44.56% change year over year.

NASDAQ: NVCR

Novocure Ltd

CEO	Mr. William F. Doyle
IPO Date	Oct. 2, 2015
Location	Jersey
Headquarters	No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Employees	1,453
Sector	Healthcare
Industry	Medical devices

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key trends